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Abstract
Introduction: In this study, we aimed to investigate the association between single nucleotide polymorphisms (SNPs) within
two genes involved in the NF-kB cascade (GPR177 and MAP3K14) and bone mineral density (BMD) assessed at different
skeletal sites, radial geometric parameters and bone turnover.
Methods: Ten GPR177 SNPs previously associated with BMD with genome-wide significance and twelve tag SNPs (r2$0.8)
within MAP3K14 (610 kb) were genotyped in 2359 men aged 40–79 years recruited from 8 centres for participation in the
European Male Aging Study (EMAS). Measurement of bone turnover markers (PINP and CTX-I) in the serum and quantitative
ultrasound (QUS) at the calcaneus were performed in all centres. Dual energy X-ray absorptiometry (DXA), at the lumbar
spine and hip, and peripheral quantitative computed tomography (pQCT), at the distal and midshaft radius, were performed
in a subsample (2 centres). Linear regression was used to test for association between the SNPs and bone measures under
an additive genetic model adjusting for study centre.
Results: We validated the associations between SNPs in GPR177 and BMDa previously reported and also observed evidence
of pleiotrophic effects on density and geometry. Rs2772300 in GPR177 was associated with increased total hip and LS BMDa,
increased total and cortical vBMD at the radius and increased cortical area, thickness and stress strain index. We also found
evidence of association with BMDa, vBMD, geometric parameters and CTX-I for SNPs in MAP3K14. None of the GPR177 and
MAP3K14 SNPs were associated with calcaneal estimated BMD measured by QUS.
Conclusion: Our findings suggest that SNPs in GPR177 and MAP3K14 involved in the NF-kB signalling pathway influence
bone mineral density, geometry and turnover in a population-based cohort of middle aged and elderly men. This adds to
the understanding of the role of genetic variation in this pathway in determining bone health.
Citation: Roshandel D, Thomson W, Pye SR, Boonen S, Borghs H, et al. (2011) Polymorphisms in Genes Involved in the NF-kB Signalling Pathway Are Associated
with Bone Mineral Density, Geometry and Turnover in Men. PLoS ONE 6(11): e28031. doi:10.1371/journal.pone.0028031
Editor: Sudha Agarwal, Ohio State University, United States of America
Received July 27, 2011; Accepted October 31, 2011; Published November 21, 2011
Copyright:  2011 Roshandel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The European Male Ageing Study (EMAS) is funded by the Commission of the European Communities Fifth Framework Programme ‘‘Quality of Life and
Management of Living Resources’’ Grant QLK6-CT-2001-00258 and supported by funding from the Arthritis Research UK. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Kate.Holliday@manchester.ac.uk
. These authors contributed equally to this work.
" Membership of the EMAS Study Group is provided in the Acknowledgments.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28031
Introduction
Osteoporosis is characterized by reduced bone mass and
deterioration in bone micro-architecture leading to bone fragility
and increased risk of fracture [1]. It is a major health problem with
the lifetime risk of fracture estimated to be about 50% and 20% at
age 50 years in women and men, respectively [2]. Prospective
studies suggest that there is a strong relationship between levels of
bone mineral density (BMD) and subsequent risk of fracture in
both men [3] and women [4,5].
Genetic factors are important determinants of bone mass.
Family and twin studies suggest that up to 80% of areal BMD
(BMDa) at the lumbar spine (LS) and hip is determined by genetic
factors [6–8]. Genome-wide association studies (GWAS) have
identified a number of loci associated with LS and hip BMDa
reaching genome-wide significance (GWS), including the genes
involved in the RANKL/RANK/OPG signalling pathway [9–12],
which have also been associated with markers of bone turnover
[13]. The RANKL/RANK/OPG signalling pathway has an
important role in bone turnover. Interaction of RANKL (receptor
activator of NF-kB ligand) with its receptor RANK (receptor
activator of NF-kB) on the surface of osteoclast precursors [14]
activates both canonical and non-canonical pathways of NF-kB.
Subsequently, active NF-kB dimers move into the nucleus, bind to
the DNA and cause gene transcription and osteoclast differenti-
ation [15]. OPG acts as a decoy receptor for RANKL and can
block its effects [14].
Rivadeneira et al. performed a meta-analysis of five GWAS of
LS and femoral neck (FN) BMDa in approximately 20,000 subjects
[10]. They strengthened the association of RANKL, RANK and
OPG with BMDa; and also identified two new loci including genes
involved in the NF-kB pathway. GPR177 is located on
chromosome 1p31.3 and single nucleotide polymorphisms (SNPs)
within this gene were associated with LS and FN BMDa at the
GWS level [10]. GPR177 which is also known as WNTLESS
homolog is an activator of the NF-kB pathway [16]. It also induces
osteoblast differentiation through the Wnt signalling pathway [17].
A single SNP on chromosome 17q12, rs9303521, which is located
about 400 kb upstream of MAP3K14, was also associated with LS
BMDa at the GWS level in the meta-analysis [10]. MAP3K14
encodes NIK (NF-kB inducing kinase) which induces production
of active NF-kB dimers in the non-canonical pathway [15].
In this study, we aimed to validate GPR177 SNP associations
with BMDa and to determine if SNPs in MAP3K14 are associated
with BMDa utilizing an independent population of middle-aged
and elderly men recruited in the European Male Aging Study
(EMAS) [18]. We also explored the influence of GPR177 and
MAP3K14 SNPs on bone geometry, another important determi-
nant of bone strength. As both genes investigated here are involved
in bone turnover related pathways, one would expect that their
effects on bone density and geometry would, at least partly, be
through altering bone turnover. Therefore, we sought to test this
hypothesis. We also investigated the combined effect of strongly
associated SNPs in RANKL, RANK, OPG, GPR177 and MAP3K14
on BMDa.
Methods
Ethics statement
Ethical approval for the study was obtained in accordance with
local institutional requirements in each centre: Florence (Ethical
Committee of the Azienda Ospedaliera Careggi & University of
Florence), Leuven (Commissie Medische Ethiek UZ Gasthuisberg
& KU Leuven), Lodz (Bioethical Committee of Medical University
of Lodz for Human Studies), Malmo¨ (Ethical Committee of Lund
University), Manchester (North West Multi Centre Ethical
Research Committee, University of Manchester & CMMCUH),
Santiago de Compostela (Comite´ E´tico de Investigacio´n Clı´nica de
Galicia & Universidad de Santiago de Compostela), Szeged
(Human Investigation Review Board, University of Szeged) and
Tartu (Ethical Committee, Medical University of Tartu). All
subjects provided written informed consent. Approval for the
genetic analysis described here was obtained for seven of the eight
centres. Therefore, analysis was restricted to subjects from these
seven centres (all centres except for Malmo¨, Sweden).
Study Participants
Men aged 40–79 years were recruited from population registers
in 8 European centres (Manchester, UK; Leuven, Belgium; Tartu,
Estonia; Lodz, Poland; Szeged, Hungary; Florence, Italy; Santiago
de Compostela, Spain; Malmo¨, Sweden) into the European Male
Ageing Study, for further details see Lee at al. (2008) [19]. Blood
samples were collected for genetic analysis. Quantitative ultra-
sound (QUS) at the calcaneus was performed in subjects at all
centres. Dual energy X-ray absorptiometry (DXA) and peripheral
quantitative computed tomography (pQCT) were performed in a
subsample of subjects in two centres (Manchester, UK and
Leuven, Belgium). Participants were excluded from this analysis if
they reported that at least one of their parents or grandparents was
born outside Europe or North America, or if they reported use of
anti-osteoporotic medications or systemic glucocorticoids.
Bone Assessments
DXA. DXA scans were performed in Manchester and Leuven
centres using a DXA QDR 4500A device (Hologic, Inc, Waltham,
MA, USA). BMDa (g/cm
2) was measured at LS (L1 to L4) and
total hip (TH). All scans and measurements were performed by
trained and experienced DXA technicians. The Hologic Spine
Phantom was scanned daily to monitor the device performance
and long-term stability. The precision of these measurements in
the LS and TH were 0.57% and 0.56% in Leuven, and 0.97% and
0.97% in Manchester, respectively. Both devices were cross-
calibrated with the European Spine Phantom [20].
pQCT. Peripheral QCT measurements were performed in
the non-dominant radius using XCT-2000 scanners (Stratec,
Pforzheim, Germany) in Manchester and Leuven centres following
the manufacturer’s standard quality assurance procedures. Total
and trabecular vBMD (mg/mm3), and bone cross-sectional area
(mm2) were measured at the distal radius (4%) (voxel size 0.4 mm).
Cortical vBMD (mg/mm3); total, cortical and medullary area
(mm2); cortical thickness (mm) and stress strain index (SSI) (mm3)
were measured at the midshaft radius (50%) (voxel size 0.6 mm).
The detailed methodology for these measurements has been
described previously [21].
The European Forearm Phantom (EFP) was measured for cross-
calibration between the two centres; 10 repeat measurements were
taken in slices 1–4. The differences were less than precision error
for total, trabecular and cortical vBMD, and cortical area.
Therefore, no cross-calibration was performed between the two
centres. The short term precision of 2 repeat measurements with
repositioning were: 2.1% and 1.3% for total vBMD; 1.27% and
1.42% for trabecular vBMD; 0.77% and 0.71% for cortical
vBMD; and 2.4% and 1.3% for cortical area; in Manchester
(n = 22) and Leuven (n = 40), respectively.
QUS. BMD at the left calcaneus was estimated by QUS using
the Sahara Clinical Sonometer (Hologic, Bedford, MA, USA) in
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all centres following a standardized protocol. Outputs included
broadband ultrasound attenuation (BUA) (dB/MHz) and speed of
sound (SOS) (m/s). Calcaneal eBMD was calculated (g/cm2) using
the following formula: BMD = 0.0025926(BUA+SOS)23.687.
The CVs were 2.8%, 0.3% and 3.4% for BUA, SOS and BMD,
respectively as described previously [13].
Bone Turnover Markers. Serum N-terminal propeptide of
type I procollagen (PINP) (ng/ml) and C-terminal cross-linked
telopeptide of type I collagen (CTX-I) (ng/ml) levels were measured
in Leuven, using electrochemiluminescence immunoassay (ECLIA)
(Roche Diagnostics) on samples from all centres. The detection limit
of PINP assay was ,5 ng/ml, and the intra-assay and inter-assay
coefficients of variations (CVs) were 0.8–2.9 and 1.8–2.9%,
respectively. The detection limit of CTX-I assay was 0.01 ng/ml,
and the intra-assay and inter-assay CVs were 2.0–5.5% and 1.0–
4.6%, respectively.
SNPs Selection
GPR177. The SNPs within GPR177 associated with LS or FN
BMDa at the genome-wide significant level (p,5610
28) in a
previous GWAS meta-analysis [10] were selected for genotyping.
Where SNPs were in high linkage disequilibrium (LD) (r2$0.8)
based on HapMap Phase II CEPH SNP data (http://www.
hapmap.org), only one of them was genotyped.
MAP3K14. Pair-wise tag SNPs (r2$0.8) were selected for
SNPs in HapMap Phase II CEPH SNP data (http://www.
hapmap.org) with a minor allele frequency (MAF) of greater than
5% within MAP3K14 and its 10 kb flanking regions using Tagger
implemented in Haploview 4.0 [22].
Genotyping and Quality Control
SNPs were genotyped using SEQUENOM MassARRAY
technology following the manufacturer’s instructions (http://
www.sequenom.com). Sample and assay quality control thresholds
were set to 90%. The SNPs deviating from Hardy-Weinberg
equilibrium (HWE), p#0.05, were excluded from the analysis.
Statistical Analysis
The outcome variables were standardised, z = (x2m)/s where
x = raw value of bone measure, m= mean of bone measure and
s= standard deviation of bone measure.
The association between the SNPs and the standardised
outcome variables (DXA: LS and TH BMDa, pQCT: radius
vBMD and geometric parameters, QUS: calcaneal BMD, and
bone turnover markers: PINP and CTX-I) was tested using linear
regression under an additive genetic model using PLINK (1.05)
[23]. The results were adjusted for study centre and also for study
centre, age, height and weight. The results are presented as a
percentage change (b) in a standard deviation (SD) with 95%
confidence intervals for each copy of the minor allele. For
significantly associated SNPs, the interaction between the SNP
and centre was tested to see if the relationship between the SNP
and the outcome differed across centres.
Pairs of SNPs associated with BMDa and located in different
genes (RANKL, RANK, OPG, GPR177 and MAP3K14) at the same
skeletal site with a p-value,0.01 were tested to determine if
carrying the risk allele (allele associated with lower BMD) for both
SNPs was associated with a greater effect on BMDa. For RANKL,
RANK and OPG, data from previous analysis in the EMAS cohort
was used [13]. In order to determine the combined effect of the
two SNPs, a new combined genotype variable was defined based
on the number of risk alleles each individual carried for either
SNP. This new variable could have a value between 0 to 4; 0:
having no copy of risk alleles for both SNPs, 1: having one copy of
risk alleles for either SNPs, 2: having two copies of risk alleles for
either SNPs, 3: having two copies of risk allele for one SNP and
one copy of risk allele for the other one, and 4: having 2 copies of
risk alleles for both SNPs. Subsequently, linear regression was used
for testing the association between BMDa and this new variable
adjusting for centre in STATA (9.2).
Results
Subject Characteristics
Of the 2658 men who consented to participate in the genetic
analysis, 299 were excluded: 180 failed sample quality control, 21
reported at least one of their parents or grandparents was born
outside Europe or North America, and 98 reported use of anti-
osteoporotic medications or systemic glucocorticoids. In total, 2359
men, mean (6SD) age 60611 years, were included in the analysis.
Bone turnover markers and ultrasound BMD were measured in
almost all men (N = 2244 and 2314, respectively). DXA and pQCT
were performed in a subsample of men from 2 centres (N = 588 and
560, respectively). Mean values of the bone turnover markers, QUS,
DXA and pQCT parameters are presented in Table 1.
Genotyping
GPR177. Thirteen SNPs within GPR177 were selected for
genotyping. Of these, 10 SNPs were successfully genotyped and
passed quality control. Rs919540, rs994082 and rs2772304 failed
genotyping.
Table 1. Mean (SD) of bone turnover markers, DXA, pQCT
and QUS parameters.
N Mean SD
Bone turnover markers
PINP (ng/ml) 2244 42.91 21.72
CTX-I (ng/ml) 2242 357.72 181.37
DXA BMDa
Lumbar spine (g/cm2) 588 1.06 0.18
Total hip (g/cm2) 587 1.02 0.14
Femoral neck (g/cm2) 587 0.81 0.13
pQCT
4% radius
Total vBMD (mg/mm3) 560 400.66 71.21
Trabecular vBMD (mg/mm3) 560 203.82 42.72
Cross-sectional area (mm2) 560 374.62 66.31
50% site
Cortical vBMD (mg/mm3) 560 1214.47 29.68
Cortical thickness (mm) 560 3.24 0.42
Total area (mm2) 560 149.31 20.72
Cortical area (mm2) 560 106.44 13.63
Medullary area (mm2) 560 42.87 15.71
SSI (mm3) 560 337.56 63.87
QUS
BMD at calcaneus (g/cm2) 2314 0.54 0.14
PINP: N-terminal propeptide of type I procollagen, CTX-I: C-terminal cross-linked
telopeptide of type I collagen, DXA: dual energy X-ray absorptiometry, BMDa:
areal bone mineral density, pQCT: peripheral quantitative computed
tomography, vBMD: volumetric bone mineral density, SSI: stress strain index,
QUS: quantitative ultrasound.
doi:10.1371/journal.pone.0028031.t001
Genetics of Bone Density, Geometry and Turnover
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e28031
MAP3K14. Forty-three SNPs with a MAF.0.05 were
identified in MAP3K14 and its 10 kb flanking regions. These
SNPs were tagged by 13 SNPs. Of these, 12 SNPs were
successfully genotyped and passed quality control covering 98%
of the selected SNPs with a MAF of more than 5% in the region.
Rs2867316 failed genotyping.
Genetic Association Analysis
For the bone turnover markers and ultrasound BMD, with
a= 0.05, there was greater than 80% power to detect differences
of 0.2 SD for SNPs with a MAF = 0.05 and 0.1 SD for SNPs with a
MAF = 0.45 under an additive genetic model. For DXA and
pQCT outcomes, with a= 0.05, there was greater than 80%
power to detect differences of 0.4 SD for SNPs with a MAF = 0.05
and 0.2 SD for SNPs with a MAF = 0.45 under an additive genetic
model. Statistical power was calculated using Quanto v1.2.3
software [24].
GPR177. Of the 10 SNPs successfully genotyped, 6 were
associated with total hip BMDa. Rs1430742, which was the most
significantly associated SNP in this locus in a GWAS meta-
analysis of LS and FN BMDa [10], showed the largest effect with
each allele resulting in a 0.18 SD (95%CI 0.04, 0.33) p = 0.015
increase in total hip BMDa. Of these 6 SNPs, 2 (rs2772300 and
rs7554551) also showed a significant association with LS BMDa
and 2 showed a non-significant effect in the same direction as
total hip BMDa but of a lesser magnitude (Table 2). Three of the
SNPs, associated with total hip BMDa, also showed a significant
association with total vBMD at the distal radius, with rs1430742
again showing the largest effect (0.15 SD (95%CI 0.02, 0.28)
p = 0.024 per allele). rs2772300, which is in moderate LD with
rs1430742 (r2 = 0.67) (Figure 1) was also significantly associated
with increased cortical vBMD at the mid-shaft radius (0.18 SD
(0.05, 0.32) p = 0.007 per allele). Other SNPs showed a change in
cortical vBMD but did not attain statistical significance.
Rs891257 was also significantly associated with increased
cortical vBMD, but was not associated with LS or TH BMDa
or total vBMD (Table 3). There was no association between any
of the SNPs and trabecular vBMD. The results were broadly
similar when applying further adjustment for age, height and
weight (Tables 2 and 3).
SNPs in GPR177 which were associated with BMD also showed
evidence of association with geometric parameters of bone
(Table 4). Two SNPs (rs2566759 and rs2195682 were associated
with cross-sectional area at the distal radius. Rs277230 and
rs1430742 were associated with increased cortical area at the mid-
shaft radius and rs2772300 was also associated with increased
cortical thickness and SSI. Rs7554551 was associated with cortical
thickness at the midshaft radius. There was no association between
SNPs in GPR177 and bone turnover markers or ultrasound
eBMD.
MAP3K14. Two SNPs showed evidence of association with
BMD. Rs8065345 was significantly associated with a 0.25 SD
(95%CI 0.10, 0.41) p = 0.002 per allele increase in LS BMDa and
was also associated with increased cortical area and cortical
thickness. Rs7215764 was significantly associated with increased
total hip BMDa and cortical vBMD at the mid-shaft radius. Three
further SNPs were associated with geometric parameters,
rs11651968 was associated with decreased cortical area at the
mid-shaft radius and rs1785379 was associated with decreased
medullary area and increased cortical thickness at the mid-shaft
radius. Rs16939948 was associated with total area at the mid-shaft
radius; however, this association became non-significant after
further adjustment for age, height and weight (Table 5). Further
adjusting the associations between MAP3K14 SNPs and bone
health parameters for age, height and weight gave broadly similar
results with effect estimates of similar magnitude. LD between the
associated SNPs was weak, r2#0.13. The results for all MAP3K14
SNPs with LS and total hip BMDa and total and cortical vBMD
are given in Tables S1 & S2 respectively.
In contrast to GPR177, there were three MAP3K14 SNPs
associated with CTX-I serum levels; rs4792847 (0.07 SD (95%CI
0.01, 0.12) p = 0.013), rs4792849 (0.06 SD (95%CI 0.00, 0.12)
p = 0.042) and rs4328483 (0.08 SD (95%CI 0.03, 0.14) p = 0.003).
None of the SNPs were associated with PINP serum levels. There
was a moderate LD between these three SNPs (0.69,r2.0.39).
There was no association between SNPs in MAP3K14 SNPs and
ultrasound BMD.
The combined effect of BMD associated SNPs in different
pathway genes
A single pair of SNPs, rs9594738 in RANKL and rs8065345 in
MAP3K14, which were both associated with LS BMDa (p = 0.001)
met the inclusion criteria for examining their combined effect. Five
Table 2. Genetic association between GPR177 SNPs and BMDa.
Total Hip BMDa LS BMDa
SNP Alleles MAF b(SD) (95% CI)a pa b(SD) (95% CI)a pb b(SD) (95% CI)a pa b(SD) (95% CI)a pb
rs2566784 G.T 0.25 0.13 (20.01, 0.26) 0.063 0.18 (0.06, 0.29) 0.003 0.11 (20.01, 0.24) 0.077 0.14 (0.03, 0.26) 0.018
rs3762371 G.A 0.4 20.07 (20.19, 0.05) 0.261 20.03 (20.14, 0.07) 0.565 20.02 (20.14, 0.09) 0.676 20.02 (20.12, 0.09) 0.74
rs2566759 A.G 0.5 20.12 (20.24, 0.00) 0.049 20.09 (20.20, 0.01) 0.088 20.04 (20.15, 0.07) 0.495 20.04 (20.15, 0.06) 0.439
rs2566758 T.C 0.46 20.13 (20.24, 20.01) 0.039 20.10 (20.21, 0.00) 0.053 20.06 (20.17, 0.06) 0.316 20.07 (20.18, 0.03) 0.187
rs1367447 C.T 0.19 0.15 (20.01, 0.30) 0.062 0.09 (20.05, 0.23) 0.208 0.07 (20.08, 0.22) 0.377 0.04 (20.10, 0.18) 0.567
rs1430742 T.C 0.23 0.18 (0.04, 0.33) 0.015 0.17 (0.04, 0.30) 0.011 0.13 (20.01, 0.27) 0.077 0.14 (0.01, 0.27) 0.036
rs2195682 C.T 0.39 20.16 (20.28, 20.04) 0.007 20.14 (20.24, 20.03) 0.011 20.11 (20.22, 0.01) 0.063 20.11 (20.21, 0.00) 0.052
rs891527 A.T 0.42 0.05 (20.07, 0.17) 0.411 0.06 (20.04, 0.17) 0.242 0.02 (20.10, 0.13) 0.751 0.04 (20.07, 0.15) 0.446
rs2772300 G.A 0.28 0.15 (0.02, 0.29) 0.026 0.18 (0.06, 0.30) 0.003 0.16 (0.03, 0.29) 0.013 0.20 (0.08, 0.32) 0.001
rs7554551 T.C 0.33 0.17 (0.05, 0.30) 0.005 0.19 (0.08, 0.29) 0.001 0.14 (0.03, 0.26) 0.016 0.17 (0.06, 0.28) 0.003
aadjusted for study centre;
badjusted for study centre, age, height and weight.
doi:10.1371/journal.pone.0028031.t002
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hundred seventy-eight subjects were included in the analysis: 5, 47,
188, 250 and 88 subjects had 0 to 4 copies of the risk alleles for
either rs9594738 in RANKL or rs8065345 in MAP3K14, respec-
tively. LS BMDa was reduced by 0.04 g/cm
2 (95% CI 20.06,
20.02) per risk alleles carried (p = 4.661026) (Figure 2).
Discussion
In this study, we investigated the association between SNPs
within two genes involved in the NF-kB cascade (GPR177 and
MAP3K14) and bone mineral density assessed at different skeletal
sites, radial geometric parameters and bone turnover. Addition-
ally, for the first time, we investigated the potential combined
effect of two associated SNPs in MAP3K14 and RANKL (previously
reported) on LS BMDa.
First, we attempted to validate the association between ten SNPs
in GPR177 and BMDa reported in a GWAS meta-analysis [10], six
of which showed significant association with total hip BMDa in the
same direction in EMAS. Two of these SNPs were also
significantly associated with LS BMDa and another 2 showed
suggestive association (p,0.1) with LS BMDa. This weaker
evidence of association with LS BMDa may have arisen due to
the presence of concomitant disease such as osteoarthritis which
can artificially raise BMD of the spine in an elderly cohort, making
it harder to detect an association, particularly in a cohort of
modest sample size. The results confirm the GWAS meta-analysis
findings and show that SNPs in GPR177 influence BMDa at
osteoporotic sites in a population of middle aged and elderly men
at that their effects can be detected in a relatively modest sample
size.
In addition, SNPs in GPR177 were also associated with total and
cortical BMD at the radius, which is a novel finding, however
despite testing in a larger sample size, there was no evidence of
association with calcaneal eBMD as measured by ultrasound, a
pattern which has been observed for other BMD susceptibility
genes [13]. The findings reported here also suggest that these
SNPs may have pleiotrophic effects on bone as SNPs associating
with cortical vBMD were also associated with geometric
parameters at the radius. Rs2772300, which was associated with
increased BMDa at the hip and LS and total and cortical vBMD at
the radius, was also associated with increased cortical area,
thickness and stress strain index. It seems unlikely that these effects
are mediated by bone turnover as no association was observed
between these SNPs and the bone turnover markers CTX-I and
PINP, in a larger sample size. Variation in the level of markers
may be one explanation for this. We attempted to reduce
variability in the bone turnover markers by taking fasting blood
samples and measuring them in a single laboratory (to reduce
technical variability). Further, the bone turnover markers selected
here (PINP and CTX-I) both had low intra-assay and inter-assay
CVs minimizing their analytical variability. Turnover marker
levels, however, reflect current skeletal turnover and may not
necessarily reflect previous levels, such misclassification may in
part explain the absence of any observed significant associations.
We also looked at the association of common SNPs
(MAF$0.05) in MAP3K14 with bone health parameters as this
gene was previously highlighted as a good candidate, however
there is no LD between the SNPs tested here in the MAP3K14
gene and the 17q12 SNP associated with BMDa [10]. There was
Table 3. Genetic association between GPR177 SNPs and BMDv.
Total vBMD (4%) Cortical vBMD (50%)
SNP Alleles MAF b(SD) (95% CI)a pa b(SD) (95% CI)a pb b(SD) (95% CI)a pa b(SD) (95% CI)a pb
rs2566784 G.T 0.25 0.08 (20.04, 0.19) 0.178 0.09 (20.02, 0.20) 0.099 0.04 (20.09, 0.18) 0.52 0.06 (20.07, 0.19) 0.365
rs3762371 G.A 0.40 20.02 (20.13, 0.08) 0.639 0.01 (20.09, 0.11) 0.887 20.03 (20.15, 0.09) 0.641 20.01 (20.12, 0.11) 0.904
rs2566759 A.G 0.50 20.05 (20.16, 0.05) 0.308 20.02 (20.12, 0.08) 0.664 20.08 (20.20, 0.04) 0.17 20.06 (20.17, 0.06) 0.331
rs2566758 T.C 0.46 20.10 (20.21, 0.00) 0.053 20.06 (20.16, 0.04) 0.222 20.09 (20.21, 0.03) 0.133 20.06 (20.18, 0.05) 0.291
rs1367447 C.T 0.19 0.12 (20.02, 0.25) 0.093 0.09 (20.04, 0.22) 0.196 0.11 (20.05, 0.27) 0.170 0.07 (20.08, 0.23) 0.362
rs1430742 T.C 0.23 0.15 (0.02, 0.28) 0.024 0.12 (0.00, 0.25) 0.057 0.11 (20.04, 0.26) 0.158 0.06 (20.09, 0.21) 0.427
rs2195682 C.T 0.39 20.10 (20.21, 0.00) 0.053 20.07 (20.17, 0.03) 0.164 20.10 (20.22, 0.02) 0.094 20.10 (20.21, 0.02) 0.108
rs891527 A.T 0.42 0.04 (20.07, 0.14) 0.504 0.02 (20.08, 0.12) 0.72 0.16 (0.04, 0.28) 0.011 0.14 (0.02, 0.25) 0.023
rs2772300 G.A 0.28 0.13 (0.01, 0.23) 0.036 0.10 (20.01, 0.22) 0.074 0.18 (0.05, 0.32) 0.007 0.15 (0.01, 0.28) 0.031
rs7554551 T.C 0.33 0.12 (0.01, 0.23) 0.028 0.10 (0.00, 0.21) 0.047 0.03 (20.09, 0.15) 0.641 0.01 (20.11, 0.13) 0.914
aadjusted for study centre;
badjusted for study centre, age, height and weight.
doi:10.1371/journal.pone.0028031.t003
Figure 1. The pair-wise LD between GPR177 SNPs associated
with bone health parameters. (black r2 = 1, white r2 = 0).
doi:10.1371/journal.pone.0028031.g001
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evidence of association between MAP3K14 SNPs and BMDa,
vBMD and radius geometric parameters, however unlike GPR177,
there were no SNPs showing association with vBMD and
geometric parameters, therefore the findings should be interpreted
with caution. This is the first time that genetic variation in the
MAP3K14 gene has been investigated with bone health parameters
and in a modest sample size, therefore replication of these findings
is required in larger cohorts.
Notably, we also found that individuals carrying risk alleles for
SNPs in the MAP3K14 and RANKL genes had a significantly lower
LS BMDa suggesting that, despite the modest effects of single
SNPs, in individuals carrying multiple risk alleles for SNPs in the
RANKL/RANK/OPG and Nf-kb signalling pathways they could
have a profound effect on bone health. This finding also requires
replication in independent cohorts.
Important potential limitations of this study are that false
positive associations might have been produced due to population
stratification and multiple testing. We tried to minimize the
probability of population stratification by excluding subjects of
non-European ancestry and did not observe any between centre
heterogeneity. However, we were unable to explore population
substructure using methods such as genomic control or principal
component analysis as these require data on a large number of
SNPs. Based on the method described by Li and Ji [25], 19
independent SNPs (GPR177: 8 and MAP3K14: 11 SNPs) were
investigated in this study. The majority of the positive findings
would not remain significant if Bonferroni correction (p,0.0026,
0.05/19) was applied to correct for multiple testing. On the other
hand, we may have missed some genuine associations due to low
statistical power. Lack of replication for association of some SNPs
with BMDa may also be due to the relatively small number of
subjects in our DXA subsample compared with the GWAS meta-
analysis. In addition, EMAS is a male population whereas the
GWAS meta-analysis data was based on studies of both men and
women.
Assessment of cortical vBMD using pQCT is subject to the
partial volume effect; the thinner the cortices the lower vBMD. In
our analysis, we used a higher threshold (960 mg/cm3) for analysis
of cortical vBMD rather than the traditional 710 mg/cm3
threshold [26] to reduce the likelihood of this effect. In addition,
most of the SNPs associated with cortical vBMD were also
associated with areal and/or volumetric BMD at other skeletal
sites but they were not associated with cortical thickness suggesting
that they are real findings rather than false positive results arising
due to technical artefact.
In summary, our findings suggest that SNPs within GPR177 and
MAP3K14 involved in the NF-kB pathway influence BMD at both
axial (LS and Hip) and peripheral sites (radius) and they also
influence radius geometry. We also found some evidence of
association between SNPs within MAP3K14 and bone turnover.
Table 4. GPR177 SNP associations with radius geometric parameters.
SNP Alleles MAF Phenotype Skeletal Site b(SD) (95% CI)a pa b(SD) (95% CI)b pb
rs2566759 A.G 0.5 Cross-sectional area 4% radius 0.11 (0.01, 0.21) 0.037 0.10 (0.00, 0.20) 0.045
rs2566758 T.C 0.46 Cross-sectional area 4% radius 0.11 (0.01, 0.22) 0.030 0.09 (0.00, 0.19) 0.060
rs1430742 T.C 0.23 Cortical area 50% radius 0.17 (0.02, 0.32) 0.031 0.14 (0.00, 0.27) 0.053
rs2772300 G.A 0.28 Cortical area 50% radius 0.17 (0.03, 0.30) 0.015 0.18 (0.05, 0.30) 0.005
Cortical Thickness 50% radius 0.17 (0.04, 0.31) 0.012 0.17 (0.04, 0.30) 0.011
SSI 50% radius 0.15 (0.01, 0.28) 0.030 0.16 (0.03, 0.28) 0.013
rs7554551 T.C 0.33 Cortical Thickness 50% radius 0.15 (0.03, 0.27) 0.018 0.15 (0.03, 0.27) 0.015
SSI: stress strain index;
aadjusted for study centre;
badjusted for study centre, age, height and weight.
doi:10.1371/journal.pone.0028031.t004
Table 5. MAP3K14 SNP associations with bone mineral density and radius geometric parameters.
SNP Alleles MAF Location Phenotype Skeletal Site b(SD) (95% CI)a pa b(SD) (95% CI)b pb
rs8065345 A.G 0.15 39 downstream BMDa Lumbar spine 0.25 (0.10, 0.41) 0.002 0.21 (0.06, 0.35) 0.006
Cortical area 50% radius 0.21 (0.05, 0.38) 0.011 0.16 (0.01, 0.31) 0.041
Cortical thickness 50% radius 0.24 (0.07, 0.40) 0.004 0.22 (0.06, 0.38) 0.006
rs11651968 C.T 0.48 39 downstream Cortical area 50% radius 20.13 (20.25, 20.01) 0.031 20.11, 20.22, 0.01) 0.062
rs7215764 C.G 0.25 39 downstream BMDa Total hip 0.17 (0.03, 0.31) 0.021 0.10 (20.03, 0.22) 0.136
Cortical vBMD 50% radius 0.17 (0.03, 0.32) 0.020 0.17 (0.03, 0.31) 0.016
rs17685379 C.G 0.14 Intronic Medullary area 50% radius 20.17 (20.35, 0.00) 0.048 20.19 (20.36, 20.02) 0.031
Cortical thickness 50% radius 0.18 (0.01, 0.35) 0.043 0.22 (0.05, 0.38) 0.011
rs16939948 T.C 0.05 Intronic Total area 50% radius 0.29 (0.01, 0.57) 0.044 0.23 (20.03, 0.50) 0.089
BMDa: areal bone mineral density, vBMD: volumetric bone mineral density;
aadjusted for study centre;
badjusted for study centre, age, height and weight.
doi:10.1371/journal.pone.0028031.t005
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However, these findings require replication in independent
populations. If confirmed, fine mapping and functional studies
will be needed to identify the causal variants. In addition,
combinations of SNPs from different genes in the NF-kB and
RANKL/RANK/OPG pathways may have substantial effects on
individuals carrying risk alleles of both SNPs highlighting the
importance of these pathways in the genetic basis of bone health.
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